NCT02130700 2018-05-07Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast CancerInnocrin PharmaceuticalPhase 2 Completed17 enrolled